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Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In the current
study, we analyzed the therapeutic eﬃcacy of the oncolytic vaccinia virus GLV-1h68 against two human prostate cancer cell
l i n e sD U - 1 4 5a n dP C - 3i nc e l lc u l t u r ea n di nt u m o rx e n o g r a f tm o d e l s .B yv i r a lp r o l i f e r a t i o na s s a y sa n dc e l ls u r v i v a lt e s t s ,w e
demonstrated that GLV-1h68 was able to infect, replicate in, and lyse these prostate cancer cells in culture. In DU-145 and PC-3
tumor xenograft models, a single intravenous injection with GLV-1h68 resulted in a signiﬁcant reduction of primary tumor size.
In addition, the GLV-1h68-infection led to strong inﬂammatory and oncolytic eﬀects resulting in drastic reduction of regional
lymph nodes with PC-3 metastases. Our data documented that the GLV-1h68 virus has a great potential for treatment of human
prostate carcinoma.
1.Introduction
Despite some progress in the diagnosis and treatment of
prostate cancer (PCa), this disease remains the second
leading cause of cancer-related death in men. The disease
accounts for an estimated 27,050 deaths in 2007 in the USA
alone [1]. Death of prostate cancer patients is normally
caused by the formation of metastases [2, 3]. At the present
time, there is no eﬀective treatment for the inhibition of
PCametastases.Therefore,thedevelopmentofnewtherapies
and diagnostics for PCa metastases is a high priority. One
of the most promising novel cancer therapies for humans
is oncolytic virotherapy. The concept that viruses may be
useful for eradication of cancer has already been conﬁrmed
by the use of several viruses, for example, Newcastle disease
virus, reovirus, lentivirus, herpes simplex virus, enterovirus,
Sindbis virus, Semliki Forest virus, Seneca Valley virus, and
vaccinia virus [4–7].
In our study, we have investigated the therapeutic poten-
tial of the oncolytic vaccinia virus GLV-1h68 in xenograft
models of human prostate cancer. The GLV-1h68 virus
was engineered by inserting expression cassettes encoding
a Renilla luciferase-green ﬂuorescent protein (Ruc-GFP)
fusion protein, β-galactosidase, and β-glucuronidase into
the genome of the LIVP strain, which is highly attenuated
compared to the wild-type strain [8]. We have already
demonstrated that the injection of GLV-1h68 leads to
regression and elimination of diﬀerent tumor xenografts in2 Journal of Biomedicine and Biotechnology
nude mice [8–13].Inaddition,Kellyetal.reportedthatGLV-
1h68 virus could be used as a tool for detection of melanoma
lymph node metastases in an immunocompetent animal
model [14]. More recently, a GLV-1h68 derivative (GLV-
1h99) that expresses the human norepinephrine transporter
was shown to be useful for both therapy and deep-tissue
imagingoftumors[15,16].Inthemeantime,moreandmore
data reported from clinical trials using oncolytic vaccinia
viruses in cancer patients have shown good safety and
promising responses [7, 17].
Here we describe that GLV-1h68 was able to infect,
replicate in, and lyse human prostate DU-145 and PC-3 cells
in culture. In addition, a single injection of GLV-1h68 into
micewithprostatetumorxenograftscouldeﬃcientlyprevent
tumor growth and formation of PC3-metastases in the
local lymph nodes. Finally, the oncolytic and immunological
eﬀects of GLV-1h68 in primary tumors and PC-3 metastases
were analyzed by ﬂuorescence imaging, immunohistochem-
istry, and an Immune-Related Protein Antigen Proﬁling.
2.MaterialsandMethods
2.1. Cell Culture. African green monkey kidney ﬁbroblasts
(CV-1) and human prostate cancer cell lines (DU-145 and
PC-3) were obtained from the American Type Culture Col-
lection(ATCC).CellswereculturedinDMEMsupplemented
with antibiotic-solution (100 units/mL penicillin G, 100
units/mL streptomycin) and 10% fetal bovine serum (FBS;
Invitrogen GmbH, Karlsruhe, Germany) at 37
◦Cu n d e r5 %
CO2.
2.2. Virus Strain. GLV-1h68 is a genetically stable oncolytic
virus strain designed to locate, enter, colonize, and destroy
cancer cells without harming healthy tissues or organs [8].
2.3. Cell Viability Assay with GLV-1h68. DU-145 and PC-
3 cells were seeded onto 24-well plates (Nunc, Wiesbaden,
Germany). After 24 hours in culture, cells were infected
with GLV-1h68 using multiplicities of infection (MOI) of
0.1 and 1. Cells were incubated at 37
◦C for 1 hour, then
the infection medium was removed and the cells were
incubated in fresh growth medium. The amount of viable
cells after infection with GLV-1h68 was measured using 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) (Sigma, Taufkirchen, Germany). At 24, 48, 72, or
96 hours after infection of cells, medium was replaced by
0.5mL MTT solution at a concentration of 2.5mg/mL MTT
dissolved in RPMI 1640 without phenol red and incubated
for 2 hours at 37
◦Ci na5 %C O 2 atmosphere. After removal
of the MTT solution, the color reaction was stopped by
adding 1 N HCl diluted in isopropanol. The optical density
was then measured at a wavelength of 570nm. Uninfected
cells were used as reference and were considered as 100%
viable. The amount of viable cells after infection with GLV-
1h68 was measured in triplicate.
2.4. Viral Replication. DU-145 and PC-3 cells grown in 24-
well plates were infected with GLV-1h68 at an MOI of 0.1.
After one hour of incubation at 37
◦C with gentle agitation
every 20 minutes, the infection medium was removed
and replaced by fresh growth medium. Supernatants were
collected from virally treated cells at 1, 6, 12, 24, 48, 72, or
96 hours postinfection. Serial dilutions of supernatants were
titrated by standard plaque assays on CV-1 cells. All samples
were measured in triplicate.
2.5. GLV-1h68 Mediated Therapy of DU-145 and PC-3
Xenografts. Tumors were generated by implanting DU-145
(1 × 107 cells in 100μL of PBS) or PC-3 cells (2.5 × 106
in 100μL PBS) subcutaneously on the right ﬂank above
the hind leg of 6- to 8-week-old male or female nude
mice (NCI/Hsd/Athymic Nude-Foxn1nu, Harlan Winkel-
mann GmbH, Borchen, Germany). Tumor growth was
recorded weekly in two dimensions using a digital caliper.
Tumor volume was calculated as [(length × width2)/2]. On
day 18 for DU-145 and on the day15 for PC-3, a single dose
oftheGLV-1h68virus(5 ×106 plaqueformingunits(pfu)in
100μL PBS) was injected into the tail vein (i.v.). The animals
of the control groups were injected i.v. with PBS only.
The signiﬁcance of the results was calculated by two-way
analysis of variance (ANOVA) with Bonferroni comparison
posttest (GraphPad Prism software, San Diego, USA). The
posttest was only performed when ANOVA revealed signif-
icance. Results are displayed as means ± s.d. P-values of
< 0.05 were considered signiﬁcant.
All animal experiments were approved by the govern-
ment of Unterfranken, Germany, and conducted according
to the German animal protection guidelines.
2.6. Histology of Tumors and Lymph Nodes. Preparation of
tissue sectioning and ﬂuorescence microscopy was carried
out as described previously [10, 18]. GLV-1h68 was labeled
using polyclonal rabbit antivaccinia virus (anti-VACV) anti-
body (Abcam, Cambridge, UK), which was stained using
Cy3-conjugated donkey antirabbit secondary antibodies
obtained from Jackson ImmunoResearch (West Grove, PA,
USA). Phalloidin-TRITC (Sigma, Taufkirchen, Germany)
was used to label actin.
MHCII-positive cells were labeled using monoclonal
rat anti-MHCII antibodies (NatuTec, Frankfurt, Germany)
and Cy3-conjugated donkey antirat secondary antibodies
(Jackson ImmunoResearch, PA, USA).
The ﬂuorescence-labeled preparations were examined
using a Leica MZ 16 FA stereoﬂuorescence microscope
equipped with Leica DC500 Digital Camera. Digital images
were processed with Photoshop 7.0 (Adobe Systems, Moun-
tain View, CA, USA) and merged to yield pseudocolored
images.
2.7. Reverse Transcription (RT)-PCR. Tumor tissue samples
were analyzed for the presence of PC-3 cells by RT-PCR. For
this purpose, regional lymph nodes with a diameter of more
than 2.5mm or PC-3 primary tumors were homogenized
in TRIzol Reagent (Invitrogen Life Technologies, Karlsruhe,
Germany) to isolate total RNA. Genomic DNA was removed
from the samples using DNA-free (Ambion, Austin, TX,Journal of Biomedicine and Biotechnology 3
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Figure 1: Cytotoxicity (a) and replication (b) of GLV-1h68 virus in human prostate DU-145 and PC-3 cells. (a) Viability of DU-145 and PC-
3 cells after GLV-1h68 infection at MOIs of 0.1 and 1, respectively, monitored over 72 hours. Values are shown as percentages of respective
uninfected controls. (b) Viral titer analysis in DU-145 and PC-3 cell cultures after infection with GLV-1h68 at an MOI of 0.1. Supernatants
were collected from virally treated cells at various time points postinfection (hpi). Viral titers were determined as pfu per well in triplicate
by plaque assay in CV-1 cell monolayers. Average plus standard deviation are plotted.
USA). RNA samples were converted to cDNA by RevertAid
First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot,
Germany) and analyzed by RT-PCR, using DNA Polymerase
(Phusion, Finnzymes, Espoo, Finland) and the primers for
human β-actin (for the identiﬁcation of PC-3 cells, forward:
5 -CCT CTC CCA AGT CCA CAC AG-3 and reverse: 5 -
CTG CCT CCA CCC ACT C-3 ); for murine β-actin (as
positive control, forward: 5 -CGT CCA TGC CCT GAG TC-
3  and reverse: 5 -GCT GCC TCA ACA CCT CAA C-3 ).
PC-3 positive samples were also analyzed for the presence
of GLV-1h68 using vaccinia virus A21L speciﬁc primers
(forward: 5 -CGT AAA CTA CAA ACG TCT AAA CAA
GAA-3 and reverse: 5 -CCT GGT ATA TCG TCT CTA TCT
TTA TCA C-3 ).
The PCR reaction was run in a T-Gradient Thermoblock
PCR machine (Biometra, G¨ ottingen, Germany) under the
following cycling conditions: 30 cycles of 95
◦C/30sec,
58
◦C/30sec, and 72
◦C/5sec.
2.8. Preparation of Tumor Lysates for a Mouse Immune-
Related Protein Antigen Proﬁling. For preparation of tumor
lysates, at 42 days after virus treatment, two mice from each
group were sacriﬁced. Tumors were removed, resuspended
in 9 volumes (W/V) lysis buﬀer [50mM Tris-HCl (pH
7.4), 2mM EDTA (pH 7.4), 2mM PMSF and Complete
Mini protease inhibitors (Roche, Mannheim, Germany)],
and lysed using FastPrep FP120 Cell Disruptor (BIO 101,
Qbiogene, Germany) at a speed of 6 for 20 seconds (three
times).Sampleswerethencentrifugedat20,000gat4◦Cfor5
minutes and the supernatants were then analyzed for mouse
immune-related protein antigen proﬁling by Multianalyte
Proﬁles (mouse MAPs; Rules Based Medicine, Austin, USA)
using antibody linked beads. Results were normalized based
on total protein concentration.
3. Results
3.1. Cytotoxicity and Replication Eﬃcacy of GLV-1h68 Virus
in Human Prostate Cancer DU-145 and PC-3 Cells. In order
to test the ability of the GLV-1h68 virus to infect and lyse
DU-145 and PC-3 cells, we performed a cell viability assay
as described in Materials and Methods. Seventy-two hours
after GLV-1h68 infection at MOIs of 0.1 and 1.0, only 1.7%
and 2.1% of the DU-145 cells and 23% and 3% of the PC-3
cells survived the treatment (Figure 1(a)).4 Journal of Biomedicine and Biotechnology
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Figure 2: Eﬀect of systemic virus injection on DU-145 xenograft
tumors. (a) DU-145 tumor development in mice after GLV-1h68-
treatment versus PBS treatment. Two-way analysis of variance
(ANOVA) with Bonferroni posttest was used to compare the
two corresponding data points of the two groups. P<. 05 was
considered as statistically signiﬁcant ∗P<. 05; ∗∗P<. 01; ∗∗∗P<
.001. (b) Body weights of DU-145 cell xenografted mice after virus
treatment.
In addition, the replication eﬃcacy of GLV-1h68 in DU-
145 and PC-3 cells was analyzed in cell culture (Figure 1(b)).
The data demonstrated that GLV-1h68 can eﬃciently repli-
cate in both prostate cancer cell lines and that the highest
virus titer was identiﬁed in supernatants at 96 hours after
infection(1.4 ×106 pfu/wellDU-145and2.94 ×106 pfu/well
PC-3,resp.).Thisresultcorrelatedverywellwithcellviability
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Figure 3: Eﬀect of systemic virus injection on tumor growth in PC-
3 xenografted mice of diﬀerent genders. Tumor-bearing mice were
i.v.injectedwitheitherasingledoseofGLV-1h68virus(5 ×106 pfu,
groupsno.1andno.3)orwith100μLPBS(groupsno.2andno.4).
Tumor volume was monitored weekly. Two-way analysis of variance
(ANOVA) with Bonferroni posttest was used to compare the two
correspondingdatapointsofthetwogroups.P< .05wasconsidered
as statistically signiﬁcant ∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001. Male
mice: groups no. 1 and no. 2, female mice groups no. 3 and no. 4.
assay data (Figure 1(a)). Generally, the GLV-1h68 virus
was able to infect, replicate in, and lyse human prostate
carcinoma DU-145 and PC-3 cells in cell culture.
3.2. Signiﬁcant Regression of DU-145 and PC-3 Derived
Tumors after a Single Systemic Administration of GLV-1h68.
To test the therapeutic capacity of GLV-1h68 against human
prostate cancer cells in vivo, nude mice at the age of 6–8
weeks were implanted with either DU-145 or PC-3 cells.
In the case of DU-145 xenografts, at day 18 post
infection, ten tumor-bearing male mice were injected with
5 × 106 pfu of GLV-1h68 (Figure 2,g r o u p1 ,n = 6) or with
PBSonly(Figure 2(a),group2,n = 4).Thedatarevealedthat
an intravenous injection of GLV-1h68 signiﬁcantly inhibited
the growth of DU-145 cell xenografts in vivo, while no
reduction of net body weight of the animals was observed
(Figure 2(b)).
In the case of PC-3 xenografts, two weeks postimplan-
tation, both male and female nude mice developed tumors
ranging from 150 to 250mm3 in size (Figure 3). At day 15,
ﬁve female or male tumor-bearing mice (groups 1 and 3,
n = 5) were injected with 5 × 106 pfu of GLV-1h68 into the
tail vein. The tumor-bearing mice of control groups 2 (PBS-
female, n = 5) and 4 (PBS-male, n = 5) were injected with
PBS only. Tumor size was measured weekly. The data showed
that a single GLV-1h68 infection caused highly signiﬁcant
PC-3-tumor regression in both female and male tumor-
bearing animals (Figure 3, groups 1 and 3), compared to the
uninfected control groups 2 and 4.Journal of Biomedicine and Biotechnology 5
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Figure 4: Immunohistochemical staining of PC-3 tumors. Male ((a) and (b)) or female ((c) and (d)) mice bearing PC-3 tumors were i.v.
injected either with PBS ((a) and (c)) or with 5 × 106 pfu of GLV-1h68 ((b) and (d)). At day 42 after injection, whole tumor cross-sections
(100μm) were labeled with Phalloidin-TRITC (red) and anti-VACV antibody (green). Scale bars = 5mm.
3.3. Viral Distribution after Tumor Regression in PC-3
Xenografts. Mice with PC-3 xenograft (groups 1 and 3,
Figure 3) were analyzed for viral distribution by standard
plaque assay or by immunohistochemical staining at day
42 after virus injection. The plaque assay analysis revealed
the presence of virus particles in primary tumors, in lungs
and in regional lumbar lymph nodes, but not in spleens of
virus-injected mice (Table 1). The highest viral titers were
identiﬁed in primary tumors of all tested mice (Table 1).
In addition, the data of immunohistochemical studies of
the primary tumors also demonstrated that GLV-1h68 was
presentthroughoutthetumortissueofbothmaleandfemale
mice(Figure 4).Asexpected,thetumorsofnoninfectedmice
were free of virus particles.
All these ﬁndings demonstrated that GLV-1h68 locates
and multiplies almost exclusively in tumor tissue.
3.4. Eﬀects of the GLV-1h68 Virus on Metastases Formation in
the Regional Lymph Nodes of PC-3 Xenograft Mice. In order
to investigate the possible eﬀects of GLV-1h68 on metastases
Table 1: Distribution of GLV-1h68 in tissues of PC-3 tumor-
bearing nude mice at day 42 after virus injection.
Tissue/Organ∗ (pfu/g) Female and male mice
Lung (n = 4) 2 .76 × 103 ±8.4 × 102
Lymph node (n = 8) 2.93 × 103 ±1.9 × 103
Tumor (n = 4) 1.69 × 106 ±5.27 × 105
Spleen n.d.
∗All mice were sacriﬁced 42 days after virus injection. The data were
determined by a standard plaque assay on CV-1 cells using aliquots of the
homogenized organs and were displayed as mean pfu/g.
Foreachorgan,twoaliquotsof0.1mLweremeasuredintriplicates.n.d.:not
detectable.
formation, we analyzed for the presence of PC-3 human
prostate cells in regional lumbar and renal lymph nodes with
an increased size (a diameter of more than 2.5mm). The
RT-PCR data revealed that at day 21 after PBS (control) or
GLV-1h68injection(correspondingto36daysafterPC-3cell
implantation)about92%ofenlargedlymphnodes(45of49)6 Journal of Biomedicine and Biotechnology
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Figure 5: Eﬀects of the GLV-1h68 virus on metastases formation in
the regional lymph nodes. (a) Percentage of PC-3 positive regional
lymph nodes in tumor-bearing mice at day 21 after PBS or virus
injection. Fisher’s exact test (GraphPad Prism software, San Diego,
USA) was used for statistical analysis. The value of P<. 001 was
considered signiﬁcant. GLV-1h68:1h68. (b) RT-PCR analysis of
tumors and regional lymph nodes of PC-3 xenograft mice injected
either with PBS or with 5 × 106 pfu of GLV-1h68 (1h68) using
primers for human beta-actin (lines 1; indicating PC-3 cancer cells,
PCR-fragment 205bp), mouse beta-actin (lines 2; positive control,
PCR-fragment 216bp), and vaccinia virus (lines 3; PCR-fragment
204bp). ln: lymph node of two diﬀerent mice.
in control mice (n = 11) and 21% of enlarged lymph nodes
(6 of 28) in GLV-1h68-treated mice (n = 11) were positive
for human beta-actin (Figure 5(a)). The presence of human
beta-actin was used as a marker for the presence of intact
human PC-3 cells; therefore, the systemic treatment by GLV-
1h68 appears to aﬀect the PC-3 metastases formation in the
regional lymph nodes. All lymph nodes that tested positively
for the presence of human beta-actin were also positive for
vaccinia virus in GLV-1h68-injected mice but not in control
mice(Figure 5(b)),indicatingthati.v.injectedGLV-1h68can
target lymph node metastases. Interestingly, the GLV-1h68
virus was detected in about 68% (19 of 28) of the lymph
nodes in the absence of PC-3 tumor cells.
3.5. Colonization of Established Metastases in the Regional
Lymph Nodes of PC-3 Xenograft Mice. In order to clarify
whether the increased inhibition of PC-3 metastases for-
mation in the regional lymph nodes was a result of the
preventative or oncolytic eﬀect of the GLV-1h68 virus, we
injected tumor-bearing nude mice (n = 4) with a single dose
of GLV-1h68 (5 × 106 pfu) at day 57 after implantation of
PC-3 cells. This time point allows the analysis of established
metastases in the regional lymph nodes of PC-3 xenograft
mice. Eleven days later, virus distribution in lymph node
metastases was analyzed either by ﬂuorescence imaging
(Figure 6) or by immunohistochemical staining (Figure 7).
The data demonstrated that GLV-1h68 can eﬃciently target
local lymph node metastases (Figure 6) and destruct tumor
tissue within these lymph nodes (Figure 7).
3.6. Mouse Immune-Related Protein Antigen Proﬁling of GLV-
1h68-Infected and Noninfected PC-3 Derived Tumors. In
order to study the immunological eﬀect of virus infection
in vivo, we analyzed the antigen proﬁling of GLV-1h68-
infected and noninfected PC-3 tumors 42 days after virus
injection. For this purpose, lysates of these tumors were used
for examination of the expression levels of immune-related
protein antigens of mouse origin, as described in Materials
and Methods.
The data revealed that GLV-1h68 injection led to
increased production of most of the tested proinﬂammatory
cytokines and chemokines (Table 2). Many of the tested
cytokines and chemokines, such as IP-10, IL-18, IL-6, MCP-
1, MCP-3, MCP-5, M-CSF, and TNF-alpha, are known to
activate macrophages, monocytes, neutrophils, eosinophils,
and, so forth, and to trigger proinﬂammatory responses in
targettissues.Incontrast,onlyonecytokine(MIP-1-gamma)
wassigniﬁcantlydownregulated upon virusinfection in both
male and female PC-3 tumor-bearing mice.
3.7. Active Peri- and Intra-Tumoral Inﬁltration of MHC Class
II-Expressing Host Cells in GLV-1h68-Infected Tumors. The
immune-related protein antigen proﬁling of regressing PC-
3-tumors revealed protein expression signatures consistent
with innate immune defense activation (Table 2). There-
fore, we analyzed the presence of innate immune system
components into the PC-3-derivated tumors by immuno-
histochemistry. In this context, we labelled MHC class II-
expressing host cells (like, e.g., macrophages and dendritic
cells) in the tumor tissue. Indeed, the data demonstrated
speciﬁc peri- and intra-tumoral inﬁltration of MHC class II-
expressing host cells surrounding virus-infected cancer cells
(Figure 8). These host cells were absent in the noninfected
control samples.
4. Discussion
Prostate cancer is the cause of more than 1% of all deaths
in men and its incidence is increasing by 2-3% per year
[19]. The available treatment options for advanced prostate
cancer are very limited and the prognosis for patients with
advanced-stage disease is poor. Therefore, there is an urgent
need to identify novel agents for therapy and diagnosis of
advanced prostate cancer.
In this study, we investigated the therapeutic eﬃcacy
of the oncolytic vaccinia virus strain GLV-1h68 against
advanced human prostate carcinoma. We examined the anti-
tumor eﬃcacy of GLV-1h68 in DU-145 and PC-3 prostateJournal of Biomedicine and Biotechnology 7
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Figure 6: Detection of lymph node metastases by GLV-1h68-mediated ﬂuorescence. (a) Bright-ﬁeld, and (b) overlay ﬂuorescence images
of renal and lumbar lymph nodes in GLV-1h68-infected mice with PC-3 tumors. a1, b1: mouse no. 1 and a2, b2: mouse no. 2. Scale bars =
2mm.
tumor xenograft models. The androgen-independent DU-
145 and PC-3 models were preferred over several androgen-
dependent xenograft models, like LAPC-4 or -9 [20, 21],
since the PC-3 cells are more aggressive [22] and more drug-
resistant than that used in androgen-dependent models [23].
It is known that the mortality of prostate cancer results from
the progression of androgen-dependent disease to androgen-
independent prostatic growth and metastases to the bones
and lymph nodes [24, 25]. Therefore, we also analyzed the
presence of PC3-metastases in the regional lymph nodes.
The tumor status of these lymph nodes provides important
information in both the diagnosis and treatment of prostate
cancer. Our PC-3 xenografts data demonstrated that GLV-
1h68 can eﬃciently target both the primary tumor and the
regional lymph nodes with metastases. These interactions
led to signiﬁcant size reduction of the primary tumor and
inhibition of metastases development in our PC-3 xenograft
models.
I no r d e rt ot e s tt h ee ﬀect of GLV-1h68 on PC-3
metastases formation, we analyzed the presence of PC-3 cells
in the regional lymph nodes at day 21 after PBS or GLV-
1h68 injection. We chose this time point because, at 21
days after the virus treatment, the growth of the primary
tumors was eﬃciently inhibited (Figure 3). We found a
signiﬁcant reduction in the number of PC-3 positive lymph
nodes in virus-treated tumor-bearing mice compared to
non-virus-treated controls (Figure 5(a)). Moreover, lymph
nodes bearing PC-3 cells in GLV-1h68-injected animals
showed also the presence of vaccinia virus (Figure 5(b)). In
addition, histological analysis revealed virus patches over the
surface of metastases, which was also associated with massive
destruction of tumor tissue when GLV-1h68 was injected
into mice with well-established PC-3 lymph node metastases
(Figure 7). Surprisingly, the GLV-1h68 virus was detected in
about 68% lymph nodes in the absence of PC-3 actin data.
In these cases, it could be that, the PC-3 cells were already
destroyed, but GLV-1h68 persisted longer in the tumor tissue
or the vaccinia virus was present in lymph nodes that were
not inﬁltrated by malignant cells. Therefore, the signiﬁcantly
reduced number of lymph node metastases in GLV-1h68-
injected PC-3 mice could be due to both the oncolytic eﬀects
of vaccinia virus colonizing lymph node metastases and the
virusprevention of metastases formation.
For a better understanding of a possible immunological
eﬀect of the GLV-1h68 virus on PC-3 xenografts, we investi-
gated the mouse immune-related protein antigen proﬁling
in the primary tumors with and without virus infection.
The data revealed that the protein expression levels of most
of the tested proinﬂammatory cytokines and chemokines
were signiﬁcantly upregulated after viral tumor colonization
(Table 2). The resulting cytokine proﬁle after GLV-1h68
infection was similar to the cytokine proﬁle in immunocom-
petent Balb/c mice [14, 26] and in an immunocompromised
nude mouse model [11]. Therefore, the cytokine proﬁle after
vaccinia virus infection seems to be relatively independent
of several factors, including: tumor origin [[11] and this
study], the number of replication-competent virus particles
reaching the tumor after injection, the route of injection
[[10], Gentschev unpublished data)], and the sex of the
mice (this study). These observations support the hypothesis
that the oncolytic eﬀect of vaccinia virus is at least in part
mediated through host defense mechanisms, most likely8 Journal of Biomedicine and Biotechnology
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Figure 7: Immunohistochemical staining of a lymph node with PC-3 metastases. At day 57 after PC-3 cells implantation, tumor-bearing
mice were injected with 5 × 106 pfu of GLV-1h68. At day 11 after virus injection, whole lumbar lymph node cross-sections were analyzed
by bright-ﬁeld imaging (a) or by ﬂuorescence microscopy techniques. (b) Phalloidin-TRITC (red) and (c) anti-VACV antibody (green), and
(d) (overlay). Scale bars = 1mm. ∗indicates the dead tumor tissue destructed by GLV-1h68.
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Figure 8: Immunohistochemistry staining of MHC class II positive cells in PC-3 tumors. (a) Forty-two days after GLV-1h68 administration
PC-3 tumors were excised, sectioned, and labeled for MHCII. In addition, GFP signals from GLV-1h68-infected cells and transmission
images are shown. (b) Overlay of MHCII and GFP signals in uninfected (left) and virus-infected PC-3 tumors (right). Scale bars = 5mm.
by the innate immune system [8, 27]. Indeed, many of
the upregulated proteins in tumor tissue (Table 2), such as
MCP-1, MCP-3, MCP-5, M-CSF, and IL-18, are involved
in activation of some components of the innate immune
system, like macrophages and neutrophils. IP-10, the most
upregulated protein in our study, has been shown to display
antitumor and antimetastatic properties [28]. This cytokine
is also known to enhance the cytolytic activity of NK cells, aJournal of Biomedicine and Biotechnology 9
Table 2: Mouse immune-related protein antigen proﬁling in PC-3-derived tumors of male or female nude mice with or without GLV-1h68
treatment at the day 42 after virus infection (n = 2). Folds of enhancement (a) or suppression (b) of mouse protein expression after virus
injection are shown. Each value was determined as the mean of triplicate determination.
(a) Upregulated protein expression levels (day 42 after virus infection).
Antigen names GLV-1h68/untreated ratio (female) GLV-1h68/untreated ratio (male) Classiﬁcation
Apo A1 2.83 2.78 Anti-inﬂammatory protein
GM-CSF 2.2 2.77 Granulocyte-macrophage
colony-stimulating factor
IL-6 8.44 6.8 Proinﬂammatory cytokine
IL-11 3.81 3.63 Pleiotropic cytokine
IL-18 30 29.72 Proinﬂammatory cytokine
IP-10 (CXCL10) 33.91 8.18 Interferon-gamma-induced
protein
MCP-1 (CCL2) 11.8 7.05 Proinﬂammatory cytokine
MCP-3 (CCL7) 6.09 3.23 Proinﬂammatory cytokine
MCP-5 (CCL12) 30.24 10.64 Proinﬂammatory cytokine
M-CSF (KC/GROα) 2.18 2.48 Proinﬂammatory cytokine
MDC (CCL22) 4.5 3.23 Proinﬂammatory
chemokine
MIP-1beta 9.09 3.31 Proinﬂammatory cytokine
MIP-2 (CXCL2) 2.9 3.33 Proinﬂammatory
chemokine
RANTES (CCL5) 7.1 4.58 Proinﬂammatory
chemokine
TIMP-1 2.6 2.43 Tissue inhibitor of
metalloproteinase type-1
TNF-alpha 2.56 2.27 Proinﬂammatory cytokine
(b) Downregulated protein expression level (day 42 after virus infection).
Antigen names Untreated GLV-1h68/ratio (female) untreated GLV-1h68/ratio (male) Classiﬁcation
MIP-1gamma (CCL9) 8 7.5 Cytokine
component of the innate immune system, and to contribute
to vaccinia virus clearance in vivo [29].
The only cytokine in our study that was signiﬁcantly
downregulated was the protein MIP-1 gamma (CCL9). MIP-
1 gamma, a small cytokine belonging to the CC chemokine
family, is secreted by the follicle-associated epithelium
and recruits CD11b+ dendritic cells [30]. Interestingly, in
some adenocarcinomas, the expression of MIP-1 gamma
is increased in the tumor epithelium [31]. However, the
eﬀect of the down-regulation of MIP-1 gamma in our PC-
3 prostate tumor xenograft models is currently unknown.
Taken together, the immune-related protein antigen pro-
ﬁling of regressing PC-3 tumors revealed protein expression
signatures consistent with innate immune defense activation
inclusive of cytokines and chemokines (Table 2). Therefore,
we analyzed the presence of some components of the innate
immune system such as macrophages, dendritic cells, and
leukocytes into the PC-3-derivated tumors by immuno-
histochemistry. The data demonstrated speciﬁc peri- and
intratumoral inﬁltration of MHC class II-expressing host
cells surrounding virus-infected cancer cells (Figure 8). The
presence of activated macrophages or dendritic cells in virus-
infected PC-3 xenografts only could serve as an evidence for
the association between xenograft eradication and immune
activation of the innate immune system. These ﬁndings
suggest that immune activation may combine with viral
oncolysis to induce tumor eradication, providing a novel
perspective for the design of oncolytic viral therapies for
humancancers.However,inourexperimentalsettings,itwas
notpossibletodistinguishbetweencomponentsoftheinnate
immune system directly involved in the killing of tumor cells
or in the elimination of vaccinia virus particles.
As described previously, we have used male and female
nude mice for analysis of the eﬀect of the GLV-1h68 virus
on PC-3 xenografts. The data demonstrated that in male
mice, GLV-1h68 injection led to a faster and more eﬃcient
tumor regression than in female mice bearing PC-3 tumors.
However, signiﬁcant tumor regression was found in both
male and female PC-3 xenografts at day 28 after virus injec-
tion. In addition, we did not ﬁnd any signiﬁcant diﬀerences10 Journal of Biomedicine and Biotechnology
in the resulting cytokine proﬁles between male and female
PC-3 xenografts after virus injection (Table 2). This means
that female nude mice could also be successfully used in
experiments with PC-3 xenografts. This is an advantage,
since the experimental handling of female animals is easier
than the handling of male animals.
Insummary,theGLV-1h68strainshowedanoutstanding
antitumor eﬀect and a safety proﬁle in DU-145 and PC-
3-xenografts. This makes it a promising candidate for the
treatment of advanced metastatic prostate cancer in human.
5. Conclusion
Our data demonstrate that the oncolytic virus GLV-1h68 can
eﬃcientlyinfectanddestroythehumanprostateDU-145and
PC-3 cells in cell culture and in vivo. In addition, a single
systemic administration of GLV-1h68 causes a signiﬁcant
inhibition of the growth of primary tumor and metastases in
PC-3 xenografts. Our ﬁndings suggest that the vaccinia virus
GLV-1h68hasthepotentialtotreatprostatecancerinhuman
patients.
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